Profound Medical (PROF)
(Delayed Data from NSDQ)
$9.08 USD
+0.12 (1.34%)
Updated Jul 9, 2024 03:57 PM ET
After-Market: $8.91 -0.17 (-1.87%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Profound Medical (PROF) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.75 | $19.00 | $9.00 | 53.46% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Profound Medical comes to $13.75. The forecasts range from a low of $9.00 to a high of $19.00. The average price target represents an increase of 53.46% from the last closing price of $8.96.
Analyst Price Targets (4 )
Broker Rating
Profound Medical currently has an average brokerage recommendation (ABR) of 1.80 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.80 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, three are Strong Buy, representing 60% of all recommendations. A month ago, Strong Buy represented 60%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PROF.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.80 | 1.80 | 1.80 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/11/2024 | Not Identified | Not Identified | Hold | Hold |
3/8/2024 | Leede Jones Gable | Douglas W Loe | Strong Buy | Strong Buy |
3/8/2024 | Not Identified | Not Identified | Hold | Hold |
3/7/2024 | Raymond James Ltd. | Rahul Sarugaser | Strong Buy | Strong Buy |
11/3/2023 | Lake Street Capital Markets | Frank Takkinen | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.80 |
ABR (Last week) | 1.80 |
# of Recs in ABR | 5 |
Average Target Price | $13.75 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 147 of 252 |
Current Quarter EPS Est: | -0.28 |